Objective -secretase/ -site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) is a key enzyme involved in Alzheimer's disease that has recently been implicated in insulin-independent glucose uptake in myotubes. However, it is presently unknown whether BACE1 and the product of its activity, soluble APP sAPP contribute to lipid-induced inflammation and insulin resistance in skeletal muscle cells.
Introduction
The primary site of insulin stimulated glucose disposal is skeletal muscle, which can account for up to 90% of glucose clearance [1] . As a result, loss of skeletal muscle insulin sensitivity is believed to be critical in the pathogenesis of type 2 diabetes mellitus (T2DM) [2, 3] . In fact, one of the earliest detectable defects in individuals at risk of T2DM is impaired skeletal muscle insulin sensitivity [4, 5] . A range of evidence suggests that insulin resistance in skeletal muscle is induced by increased levels of plasma non-esterified free fatty acids (NEFAs) [6, 7] and/or changes in adipokine levels caused by obesity [8] . It has long been recognized that elevated plasma NEFA levels cause insulin resistance in humans [9] . The mechanisms underlying the association between elevated NEFA and insulin resistance are currently unclear, but accumulating evidence points to a link between enhanced NEFA levels and activation of a chronic lowlevel inflammatory process [8, 10] . Elevated saturated NEFA can induce inflammation, and thus insulin resistance, through several mechanisms, including accumulation of fatty acid (FA) derivatives (such as ceramide and diacylglycerol) due to an increased FA flux in skeletal muscle cells that exceeds theiroxidation capacity [11, 12] , activation of toll-like receptors [13] , and endoplasmic reticulum (ER) stress [14, 15] . Of note, all these mechanisms converge in the activation of pro-inflammatory signaling pathways, including I kinase --nuclear factor (NF)-B, which has been linked to FA-induced impairment of insulin action in skeletal muscle [16, 17] . Thus, IKK-phosphorylates IRS-1 on serine residues, attenuating the insulin signaling pathway, whereas once activated, NF-B regulates the expression of multiple inflammatory mediators, including interleukin 6 (IL-6), monocyte chemoattractant protein 1 (MCP-1), and tumor necrosis factor (TNF-, which also contribute to insulin resistance [10] . Recent evidence also points to a possible defect in mitochondrial function induced by FA overload. For instance, short-term exposure to high circulating FA impairs the mitochondrial membrane potential [6] and tissue culture studies demonstrate that palmitate overload induces mitochondrial dysfunction associated with reduced oxidative capacity [17] . Mitochondrial function is transcriptionally controlled by peroxisome proliferator-activated receptor co-activator 1 (PGC-1 ) [18] and plays a critical role in skeletal muscle metabolic function. Some [19, 20] but not all [21] studies indicate a reduction in PGC-1 expression and or
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4 function in the skeletal muscle of prediabetic and diabetic subjects. Collectively, these data indicate a possible molecular link between elevated circulating FA and the impaired mitochondrial function sometimes noted in the skeletal muscle of those at risk of T2DM.
Interestingly, some Alzheimer's disease (AD) patients exhibit impaired glucose metabolism, hyperinsulinemia, and insulin resistance [22, 23] , suggesting that some common pathways may be involved in the development of both diseases. -secretase/ -site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) is a key enzyme involved in AD that has recently been implicated in insulin-independent glucose metabolism [24] . APP is first cleaved by either BACE1 or α-secretase enzyme, generating extracellular soluble APPβ (sAPPβ) or sAPPα, respectively. Following BACE1 cleavage, the APP C-terminal fragment C99 can be cleaved by γ-secretase, raising the levels of amyloid-β (Aβ) peptides and leading to amyloid aggregation and plaque formation [25] . It has been reported that BACE1-deficient mice are protected against high-fat diet (HFD)-induced glucose intolerance [26] , although the mechanisms involved remain unclear. More recently, it has been shown that inhibition of muscle BACE1 activity increases insulinindependent glucose uptake and GLUT4 translocation [24] . Of note, the saturated FA palmitate and ceramide increase BACE1 protein levels in C2C12 myotubes [24] , probably by post-translational stabilization of the protein [27] , suggesting that -secretase might contribute to the effects of saturated NEFA on inflammation and insulin resistance in skeletal muscle cells. In the present study, we examined whether BACE1 activity and its product sAPP contribute to insulin resistance in skeletal muscle.
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Materials and Methods

Cell culture
Mouse C2C12 myoblasts (ATCC) were maintained in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 50 units/ml penicillin and 50 mg/ml streptomycin.
When cells reached confluence, the medium was switched to the differentiation medium containing DMEM and 2% horse serum, which was changed every other day. After 4 additional days, the differentiated C2C12 cells had fused into myotubes. Lipid-containing media were prepared by conjugation of non-esterified fatty acids (NEFA) with NEFA-free bovine serum albumin. Briefly, palmitic acid was dissolved in ethanol and diluted 1:100 in DMEM containing 2% (w/v) NEFA-free bovine serum albumin.
Myotubes were incubated in serum-free DMEM containing 2% bovine serum albumin in either the presence (palmitate-treated cells) or absence (control cells) of NEFA. Cell viability was assessed using the LDH Cytotoxicity Assay Kit from Thermo Scientific (Waltham, MA, USA).
Human LHCN-M2 myoblasts were maintained, grown and differentiated to myotubes as previously described [28] .
Mice
Male Bace1 In a second study male C57BL/6 mice were randomly distributed into two groups (n=6 each) and intramuscular (gastrocnemius) injection of vehicle (PBS plus 4% urea) or 5 µg of sAPP was performed.
Twelve hours later animals were sacrificed and the skeletal muscle gastrocnemius was excised.
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In a third study male C57BL/6 mice were randomly distributed into two groups (n=6 each) and vehicle or 10 µg of sAPP was administered (i.p.) twice (20.00 h and 8.00 h) before starting either a glucose tolerance test (GTT) or an insulin tolerance test (ITT). In the GTT animals received 2 g/Kg body weight of glucose by ip injection, and blood was collected from the tail vein after 0, 15, 30, 60 and 120 min. In the ITT each animal received 0.5 IU/Kg of body weight of insulin.
All animal care, experimental protocols and procedures were performed in accordance to the Animal Scientific Procedures Act (1986), with approval of the University of Barcelona and Dundee ethics committees.
Subjects
Subjects were recruited by the Endocrinology Department at the University Hospital Joan XXIII (Tarragona, Spain) in accordance with the Helsinki Declaration (2008). All participants gave their informed consent and the study was approved by the respective local Ethic Committee review board of the participating Hospital. Donors were classified as lean or obese based on body mass index (BMI) following
World Health Organization criteria (WHO). T2D subjects were diagnosed according WHO criteria. All patients had fasted overnight before collection of blood samples. Anthropometric and biochemical variables from the two cohorts used are presented in Supplementary Tables S1 and S2 . All subjects were of white origin and reported that their body weight had been stable for at least 3 months prior to the study.
They had no systemic disease other than obesity, and all had been free of infection in the previous month before the study. Primary liver disease, cardiovascular disease, arthritis, acute inflammatory disease, infectious disease, neoplastic and renal diseases were specifically excluded by biochemical evaluation.
Serum was immediately separated by centrifugation and stored at −80º C until analysis. Subjects were stratified according to age, gender and BMI. The hospital ethics committee approved the study and informed consent for biobanking surgically removed tissue was obtained from all participants in accordance with the Declaration of Helsinki. All patients had fasted overnight before collection of adipose tissue and blood. Visceral (VAT) and subcutaneous (SAT) adipose tissue was obtained during scheduled non-acute surgical procedures including laparoscopic surgery for hiatus hernia repair or cholecystectomies.
A C C E P T E D M A N U S C R I P T For western blot analysis of sAPP in human serum samples, serum albumin and the major subclasses of gamma globulin (IgG) were removed using Amicon Ultra-0.5 centrifugal Filter devices (Millipore)
following Pierce Albumin/IgG Removal Kit (Pierce Biotechnology, Boston, MA).
RNA preparation and quantitative Real-Time RT-PCR
The relative levels of specific mRNAs were assessed by Real Time RT-PCR, as previously described [28] .
Primer sequences used are displayed in supplemental Table S3 .
Immunoblotting
Isolation of total and nuclear extracts was performed as described elsewhere [28] . antibodies showed a single distinct band at the molecular weight indicated in the datasheets.
Electrophoretic mobility shift assay (EMSA)
The electrophoretic mobility shift assay (EMSA) was performed as previously described [28] .
Fatty acid oxidation (FAO) assay
Total FAO was measured as previously described [29] .
Protein kinase A (PKA) activity and cAMP levels
Commercial kits were used to assess PKA activity (Enzo Life Sciences, Farmingdale, NY) and cAMP levels (Biovision, Milpitas, CA). were lysed with 0.1 mol/l NaOH. Non-specific uptake was measured in the presence of 10μmol/l cytochalasin B and was subtracted from all the values.
Pyruvate tolerance test (PTT)
For PTT analysis, mice were fasted for 15 h and intraperitoneally injected with pyruvate (2 g /Kg). Blood was taken from tail vein at 0, 15, 30, 45, 60, 75, 90, 105, and 120 min after pyruvate injection and blood glucose was measured with a glucometer.
Statistical Analyses
Results were normalised to levels in control groups and are expressed as means S.D. Significant differences were established by either the Student's t test or one-way and two-way ANOVA, according to the number of groups compared, using GraphPad Prism software (GraphPad Software Inc. V4.03, San Diego, CA). When significant variations were found by two-way ANOVA, the Tukey-Kramer multiple comparison post-test was performed. Differences were considered significant at P<0.05.
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Results
Palmitate increases Bace1 expression through an NF-B-dependent mechanism
It has been previously reported that palmitate treatment increases BACE1 protein levels in C2C12 myotubes through post-translational stabilization of BACE1 protein caused by palmitate and ceramide [24, 27] . However, it was unknown whether transcriptional mechanisms were involved. Interestingly, palmitate increased Bace1 mRNA levels in C2C12 myotubes ( Figure 1A ). Since palmitate increases NF-B activity in myotubes [12] and Bace1 is under the transcriptional control of NF-B [30] , we evaluated whether palmitate-induced NF-B activation was responsible for the increase in Bace1 expression by using the NF-κB inhibitor parthenolide [31] . Parthenolide prevented the palmitate-induced increase in Bace1 mRNA levels ( Figure 1B ), suggesting that palmitate increases its expression by activating NF-B.
Therefore, the observed increase in BACE1 protein levels following palmitate exposure ( Figure 1C ) might be the result of the reported post-translational stabilization of BACE1 protein [24, 27] , but also of Bace1 increased expression. When mice were fed a HFD we also observed an increase in the mRNA and protein levels of BACE1 in the skeletal muscle and white adipose tissue of these mice compared to those fed a standard diet ( Figure 1D -G), suggesting that the transcriptional mechanism may also operate in vivo.
BACE1 inhibition prevents palmitate-induced ER stress, inflammation, and insulin resistance
Next, we hypothesized that BACE1 might contribute to some of the deleterious effects of palmitate, including ER stress, inflammation, and insulin resistance. To elucidate this, we used the BACE1 inhibitor Merck-3 (M3), reported to inhibit BACE1 activity in C2C12 cells [24, 27] . M3 treatment significantly attenuated the palmitate-mediated increase in the expression of ER stress markers (sXbp1, Atf3, Chop, and Bip) (Figures 2A and B) . Given the association of ER stress with inflammation and insulin resistance [15] , we also evaluated the effect of M3 on palmitate-induced Tnf-and Il-6 expression. The increase in IL-6
and Tnf-expression caused by palmitate was significantly blunted in the presence of M3 ( Figure 2B ). As expected, palmitate exposure reduced protein levels of the NF-B inhibitor I B , whereas in the presence of palmitate plus M3, this reduction was blunted ( Figure 2C ). Consistent with this, the nuclear protein
levels of the NF-B subunit p65 were raised by palmitate, but this increase was abolished when cells were co-incubated with the FA and M3 ( Figure 2C ). Likewise, NF-B DNA-binding activity increased (complex I) in nuclear extracts from palmitate-exposed cells, whereas the binding activity in cells co-incubated with palmitate and M3 was similar to that observed in control cells ( Figure 2D ).
When we evaluated the insulin signaling pathway, we observed that, in agreement with a previous study reporting that ER stress reduced insulin receptor (IR) levels in adipocytes [32] , protein levels of IR were reduced in palmitate-exposed cells, which was prevented by M3 ( Figure 2E ). In line with activation of the NF-B pathway, IRS1 phosphorylation at Ser 307 was increased in palmitate-exposed cells and this was blocked by M3 ( Figure 2E ). Finally, palmitate reduced insulin-stimulated Akt phosphorylation, whereas this reduction was reversed in cells co-incubated with palmitate and M3 ( Figure 2F ). Figure 1A) , suggesting that basal expression of these genes may be repressed by BACE1 activity.
BACE1 inhibition prevents the reduction in
Bace1 knockdown increases PGC-1 in myotubes and skeletal muscle
To clearly demonstrate that BACE1 modulates PGC-1 we used genetic approaches. Knockdown of and IR protein levels were also increased, whereas phospho-IRS1 (Ser 307 ) levels were decreased ( Figure   3D ). In agreement with this, a significant increase in PGC-1 expression and protein levels in skeletal muscle from Bace1-deficient mice was observed Figures 3E and F Moreover, PPAR and PPAR / expression and protein levels were also enhanced. Likewise, the expression of I b , Cpt-1 , Acox, and
Mcad was increased in Bace1-deficient mice, whereas Mcp-1, Tnf-and Chop expression was decreased compared with wild-type littermates ( Figure 3G ). Similarly, the protein levels of I B and IR were increased in the skeletal muscle of Bace1-deficient mice compared with wild-type littermates, whereas phospho-eIF2 , which induces Chop levels, and phospho-IRS1 (Ser 307 ) were decreased ( Figure 3H ).
Bace1 knockdown prevents the reduction in PGC1 expression and the inflammatory process caused by a HFD in skeletal muscle
When we evaluated the effects of a HFD in the skeletal muscle of wild-type and BACE1-deficient mice, a reduction in Pgc-1 expression was observed in wild-type mice fed a HFD, but the increase in the expression of this co-activator displayed in BACE1 -/-mice prevented the reduction in Pgc-1 mRNA levels
when these mice were fed a HFD ( Figure 3I ). Consistent with the reduction in Pgc-1 expression, Ppar mRNA levels were also down-regulated in the skeletal muscle of wild-type mice fed a HFD, whereas this reduction was prevented in BACE1 -/-mice fed the HFD. Likewise, the HFD reduced I b expression, whereas that of Tnf-and Il-6 was increased in wild-type mice and these changes were prevented in BACE1-deficient mice fed a HFD ( Figure 3I ).
sAPP mimics the effects of palmitate
BACE1 cleaves APP releasing sAPP , which we hypothesized might be responsible for the effects caused by BACE1 in palmitate-exposed cells. sAPP concentration was selected after performing curveconcentration studies (Supplementary Figures 1D-G ). sAPP caused a reduction similar to that caused by palmitate in Pgc-1 mRNA ( Figure 4A ) and protein levels ( Figure 4B ). In agreement with this, the mRNA Figures 2B and C) . Consistent with the reduction in the attenuation of the insulin signaling pathway, sAPP also reduced insulin-stimulated glucose uptake, whereas sAPP did not ( Figure   4I ). Since our findings indicate that BACE1 activity and sAPP regulate the expression of genes involved in FAO, we next determined whether the changes in the expression of these genes affected FAO in myotubes exposed to palmitate in the presence or absence of M3 and to sAPP . Palmitate significantly reduced FAO and this effect was blunted by co-incubation with M3, while sAPP caused a reduction in FAO similar to that observed for palmitate ( Figure 4J ).
BACE1 expression and plasma sAPP levels are increased in type 2 diabetic patients
Next, we explored whether the relationship between BACE1 and PGC-1 was also observed in humans. In subcutaneous white adipose tissue (WAT) BACE1 expression was increased in obese and especially in type 2 diabetic patients compared with lean subjects ( Figure 5A ). Interestingly, this increase was accompanied by a reduction in PGC-mRNA levels. These changes were not observed in visceral WAT, where the expression of BACE1 was higher than in subcutaneous WAT (Supplementary Figures 2D) . Interestingly, mice fed a HFD exhibited higher plasma sAPP levels compared to mice fed a standard diet, whereas no changes were observed in A 42 ( Figure 5B ). In humans, although no changes were observed between obese and lean subjects ( Figure 5C ), a significant increase was observed in plasma sAPP levels from type 2 diabetic patients compared with obese non-diabetic subjects ( Figure 5D ). Interestingly, a unique intramuscular injection of sAPP in gastrocnemius muscle resulted in an increase in the expression of Chop and Atf3, whereas BiP levels were not affected ( Figure 5E ). sAPP also upregulated Tnf and Il-6 expression ( Figure 5F ), whereas a reduction in Pgc-1 and Ppar mRNA levels was observed ( Figure 5G ).
Likewise, PGC-1 and protein levels were decreased in skeletal muscle following in situ administration of sAPP , while phospho-eIF2 and BiP protein levels were enhanced ( Figure 5H ).
sAPP administration to mice induces ER stress, inflammation and reduces PGC-1
Surprisingly, intraperitoneal acute administration of sAPP (10 µg/mouse) before (20.00 h) and after (8.00
h) an overnight fasting to conduct a GTT resulted in a reduction in blood glucose levels ( Figure 6A ) and decreased the AUC of plasma glucose levels in the GTT ( Figure 6B ). In contrast, the AUC of plasma glucose levels was increased by sAPP in the ITT, indicating a reduction in insulin sensitivity ( Figure 6B ).
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sAPP administration caused an increase in the plasma levels of this peptide (Supplementary Figure 2E) similar to that caused by HFD and this led to upregulation of Atf3, Tnf and IL-6 expression in skeletal muscle, whereas no significant changes were observed in BiP and Chop ( Figure 6C ). Consistent with the increased expression of inflammatory markers, the protein levels of I B were decreased by sAPP administration, whereas BiP protein abundance was increased ( Figure 6D ). sAPP administration also reduced Pgc-1 expression and protein levels and the mRNA abundance of Ppar in skeletal muscle ( Figures 6E-F) . Consistent with the reduction in insulin sensitivity suggested by the ITT, IR protein abundance was reduced and the levels of phospho-IRS1 (Ser Figure 6H ). PGC-1 promotes hepatic gluconeogenesis by regulating the expression of rate-limiting gluconeogenic genes such as PEPCK and G6Pase [38] and in agreement with the reduction in plasma glucose levels and in hepatic Pgc-1 expression in mice treated with sAPP , these mice also exhibit a reduction in hepatic Pepck and G6Pase expression ( Figure 6H ). To clearly demonstrate that sAPPβ affects gluconeogenesis in liver we performed a PTT. As shown in Figure   6K , sAPPβ repressed glucose synthesis from pyruvate.
BACE1 regulates CREB phosphorylation
Next, we focused on the potential mechanisms by which BACE1 and sAPP regulate the expression of Pgc-1 , since its reduction seems to be the main step driving the changes caused by palmitate-induced upregulation of -secretase. Pgc-1 expression is regulated by the transcription factor CREB [39, 40] . CREB is activated following phosphorylation at Ser 133 by PKA, which is allosterically activated by cAMP [41] .
Phosphorylated CREB then interacts with the transcription co-activator CREB-binding protein to initiate
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the transcription and translation of CREB-target genes, such as Pgc-1 . Of note, it has previously been reported that elevated BACE1 protein levels reduce CREB phosphorylation, PKA activity, and cAMP levels in neuroblastoma cells and rat primary cortical neurons, contributing to memory and cognitive deficits typical of AD [42] . We hypothesized that palmitate-induced BACE1 protein levels might affect CREB phosphorylation, leading to decreased Pgc-1 expression, which contributes to reduce FAO, thereby exacerbating inflammation and insulin resistance. First, we examined whether BACE1 inhibition and sAPP affected the PKA/CREB pathway. Exposure to palmitate and sAPP reduced phospho-CREB (Ser 133 ) levels, whereas the reduction caused by palmitate was prevented by pre-treatment with M3
( Figures 7A and B) . Consistent with this, increased levels of phospho-CREB were observed following Bace1 knockdown in myotubes and in skeletal muscle of BACE1 -/-mice ( Figures 7C and D) . Exposure to palmitate reduced phospho-protein levels (Thr 197 ) of the catalytic subunit of PKA ( Figure 7E ), which is required for full catalytic activity of this kinase [43] , and this reduction was blunted by M3. sAPP caused a stronger reduction in phospho-PKA protein levels than that observed for palmitate ( Figure 7F ). Likewise, Bace1 knockdown in myotubes and BACE1-deficiency in skeletal muscle resulted in increased levels of phospho-PKA ( Figure 7G and H). In addition, PKA activity was reduced following exposure to sAPP and palmitate, the latter being reversed by pre-treatment with M3 ( Figure 7I ). Finally, cells exposed to palmitate and sAPP also showed a reduction in cAMP levels, whereas M3 pre-treatment prevented the reduction caused by the FA ( Figure 7J ). Moreover, Chen et al. [42] demonstrated that BACE1 may also reduce the cAMP/PKA/CREB pathway by interacting with adenylate cyclase. To examine whether palmitate affects the interaction between BACE1 and adenylate cyclase, we performed protein coimmunoprecipitation. In agreement with the increase in protein levels caused by palmitate, this FA raised the interaction between adenylate cyclase and BACE1, whereas this increase was prevented in cells exposed to palmitate plus M3 ( Figure 7K ).
We then examined whether sAPP also affected the interaction between BACE1 and AC. Interestingly, mice treated with sAPP showed an increase in the protein levels of BACE1 in skeletal muscle ( Figure   8A ), suggesting that it has a similar effect to that shown for palmitate. In addition, sAPP enhanced the
17 expression of Bace1 and reduced the mRNA levels of Pgc-1 in C2C12 myotubes and these changes were prevented by the NF-B inhibitor parthenolide, suggesting that they were dependent on the activation of this transcription factor ( Figure 8B ). Likewise, the protein levels of both BACE1 and PGC-1 showed the same behavior ( Figure 8C ). Finally, co-immunoprecipitation studies demonstrated that C2C12 myotubes exposed to sAPP showed enhanced interaction between BACE1 and AC and that this interaction was prevented by parthenolide ( Figure 8D ). Moreover, this interaction was also increased in the skeletal muscle of mice treated with sAPP ( Figure 8E ).
Discussion
The findings of the present study indicate that the increase in BACE1 levels caused by palmitate can contribute to lipid-induced ER stress, inflammation, and insulin resistance in skeletal muscle cells and these effects can be attenuated by BACE1 inhibition. Our findings demonstrate that the BACE1 product sAPP mimicked most of the effects of palmitate. This is the first time these network interactions have been demonstrated and add an important dimension to the mechanisms driving insulin resistance.
The changes caused by palmitate and sAPP might be the result of the reduction in PGC-1 . Furthermore, the effects observed in skeletal muscle from Bace1-deficient mice confirmed that BACE1 contributes to reduce PGC-1 levels. This transcriptional co-activator preserves OXPHOS genes [37] and co-activates and increases the expression of transcription factors involved in FAO, such as PPAR and PPAR / [33, 34] . Therefore, the reduction in PGC-1 levels caused by palmitate and sAPP may reduce FAO, increasing the amount of palmitate available and ultimately exacerbating ER stress, inflammation, and insulin resistance. In addition, PGC-1 has a role in inflammation in skeletal muscle. For instance, PGC-1 knockout mice show higher basal mRNA expression of Tnf-and Il-6 in skeletal muscle compared with wild-type mice [44] [45] [46] .
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Although it has been reported that A 42 induces hepatic insulin resistance by activating the JAK2/STAT3/SOCS1 pathway [47] , we did not observe changes in these pathway in C2C12 myotubes exposed to sAPP or in mice treated with this peptide (Supplementary Figure 3) .
On the other hand, despite it has been previously reported that PGC-1 regulates Bace1 promoter in neurons [48] , in myotubes this mechanism does not seem operate, since when Pgc-1 was overexpressed in human LHCN-M2 cells, no changes were observed in the expression of Bace1 (Supplementary Figure   4) . On the other hand, CREB binding to the PGC-1 promoter plays a key role in activating PGC-1 expression in skeletal muscle [33] , and a previous study reported that BACE1 reduces CREB phosphorylation in neurons [42] . In addition, CREB is phosphorylated by PKA following activation by cAMP. Our findings suggest that BACE1 activity down-regulates PGC-1 levels by attenuating the cAMP-PKA-CREB pathway. In neurons, there are conflicting results about whether the effects of BACE1 on the cAMP/PKA/CREB pathway are dependent on its enzymatic activity and A levels [42, 49] . Tong et al. [49] reported that A -(1-42) suppressed CREB phosphorylation in cortical neurons. In contrast, Chen et al. [42] demonstrated that enhanced BACE1 levels reduced CREB phosphorylation, PKA activity, and cAMP content in neurons and mouse brains, and that these effects were independent of BACE1 activity and A levels. These latter authors reported that BACE1 interacts via its transmembrane domain with adenylate cyclase to inactivate the cAMP/PKA/CREB pathway. Our findings also show that palmitate exposure, likely as the result of the increase in BACE1 protein levels, enhances its interaction with adenylate cyclase, a mechanism that may also contribute to reduce cAMP levels, as previously reported [42] . Although it has been reported that endogenous carnitine stores in L6 myotubes are low [50] and this may lead to cytotoxic responses of the myocytes when incubated for 24 with palmitate alone, we did not observe differences in cell viability or in some of the parameters analyzed in the absence or in the presence of carnitine for 16 h (Supplementary Figure 5) .
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The levels of sAPP were increased in plasma of mice fed a HFD, which is consistent with the reported increase in myotubes incubated with the FA-derivative ceramide [24] , whereas the levels of A -42 were not altered. In humans we found that BACE1 expression was increased in the subcutaneous WAT of obese and, especially in type 2 diabetic patients compared with lean subjects and this increase was accompanied by a reduction in PGC-1 mRNA levels. In agreement with the increase in BACE1 expression in subcutaneous WAT, sAPP plasma levels were also enhanced in obese type 2 diabetic patients compared with obese non-diabetic subjects. The lack of increase in obese subjects compared with lean subjects suggests that the increase in the levels of plasma sAPP might be associated with the transition from obesity to T2DM. Acute administration of sAPP to mice elicited similar effects to those observed in vitro,
causing an upregulation of the markers of ER stress, inflammation and insulin resistance in skeletal muscle.
Interestingly, our findings show that sAPP mimics the effects of palmitate and both increase the levels of BACE1 through an NF-B-dependent mechanism. In fact, it has been reported that NF-B increases BACE1 expression by promoter transactivation [30] . Moreover, inhibition of NF-B prevented the interaction between BACE1 and AC. Therefore, these data suggest that palmitate and sAPP increase the protein levels of BACE1 and as a result of this increase BACE1 binds and inhibits the activity of AC, ultimately leading to the reduction of the cAMP-PKA-CREB pathway and the reduction in Pgc-1 expression ( Figure 8E ).
Mice treated with sAPP showed a reduction in insulin sensitivity in the ITT, but surprisingly, plasma glucose levels were reduced by sAPP administration. No significant changes were observed in insulin levels during the GTT (Supplementary Figure 6) . In liver, PGC-1 promotes hepatic gluconeogenesis [43] , and sAPP reduced hepatic PGC-1 levels and the expression of genes regulated by this transcriptional coactivator involved in gluconeogenesis. Since PGC-1 has opposite effects on hepatic and muscle insulin sensitivity [51] , and gluconeogenesis strongly contributes to sustain plasma glucose levels under fasting conditions, for instance when glycogen stores are low after an overnight fast, the net result of a decrease in PGC-1 levels following sAPP treatment is a reduction in plasma glucose levels.
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On the basis of our findings, we propose that BACE1 and its product sAPP contribute to lipid-induced ER stress, inflammation, and insulin resistance in skeletal muscle, and that targeting BACE1 may provide a new therapeutic option for the prevention and treatment of insulin resistance and T2DM.
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Highlights
. BACE1 inhibition prevents palmitate-induced ER stress, inflammation, and insulin resistance in myotubes. . BACE1 expression and plasma sAPP levels are increased in type 2 diabetic patients.
. sAPP administration to mice induces ER stress, inflammation and reduces PGC-1 in skeletal muscle. . The BACE1 product sAPP is a key determinant in ER stress, inflammation and insulin resistance in skeletal muscle and gluconeogenesis in liver.
ACCEPTED MANUSCRIPT
Figure 1 
